CHRISTINE KARELL: Open Payments
NPI 1053480590 · ALLIANCE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 43 payments from 10 companies in 2025. Trend: 2023 $759 · 2024 $546 · 2025 $899
Food & beverage: $828Education: $71
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $261 |
| ABBVIE INC. | 6 | $157 |
| Otsuka America Pharmaceutical, Inc. | 7 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $141 |
| Alkermes, Inc. | 4 | $70 |
| Lilly USA, LLC | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, UZEDY, CAPLYTA, ABILIFY MAINTENA, ARISTADA, REXULTI, AUSTEDO XR, Auvelity.
Industry payments across NE — which companies pay providers there.
